Spectrum Pharmaceuticals Inc. (SPPI) announced Tuesday that the interim data from its Phase 2 clinical study of poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer was presented in Yokohama, Japan.
AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a trial of ANB020 Tuesday morning. An Eczema Area Severity Index score improvement of 50 percent relative to enrollment baseline was observed in 75 percent of patients after a single dose.
Constellation Brands Inc. (STZ) reported second quarter EPS of $2.47 Thursday morning, up from $1.77 a year ago. Analysts expected EPS of $2.17. The company also increased its full year EPS forecast on a comparable basis to between $8.25 and $8.40, from prior expectations of $7.90 to $8.10. The consensus estimate is for EPS of $8.18.
Zogenix Inc. (ZGNX) announced Friday morning that its Phase 3 trial of ZX008, for the treatment of Dravet syndrome, met its primary objective and demonstrated statistically significant improvements versus placebo in all key secondary measures.